关注的艺术家
每周热门曲目
未找到任何曲目
- 男性
- 社交链接
- 他是
-
Commanders and medical boards may consider whether the therapy affects physical readiness, cognitive function, mood, or cardiovascular risk. To the extent that this increase in use of testosterone supplementation is based on anticipated improvements in cardiovascular health, sexual function, physical functioning, mood, or cognition, we suggest that it might represent therapy without adequate clinical trial support. Observational studies attributing positive health effects to testosterone may be affected by an increased likelihood of healthier men being prescribed testosterone rather than testosterone improving health. A Medicare-based study identified testosterone exposures and MI outcomes using claims data and matched testosterone-treated with untreated subjects using an empirically derived propensity score and found no increased risk. Men who were treated with testosterone had an increased risk of all-cause mortality, MI, and stroke compared to men who did not use testosterone (HR, 1.29; 95% CI, 1.05–1.58), based on a mean of 27.5 months of follow-up. A Veterans Administration study evaluated men who had undergone coronary angiography and had a total testosterone concentration (presumably plasma) less than 300 ng/dL (10.4 nM).
After 180 days of treatment, only 1 patient in the 50mg gel arm, 3 patients in the 100mg gel arm, and no patients in the testosterone patch arm were found to have gynecomastia. Hyperprolactinemia is an uncommon condition172, 173 but it is a well-established cause of secondary (central) testosterone deficiency and can lead to infertility, decreased libido, sexual dysfunction, and gynecomastia. Hypergonadotropic hypogonadism, which is not a contraindication to begin testosterone therapy, can result from a number of conditions, including congenital abnormalities (KS being the most common), iatrogenic causes (e.g., bilateral orchiectomy, testicular radiation, chemotherapy), testicular trauma, infection, or autoimmune damage. A low or low/normal LH level points to a secondary (central) hypothalamic-pituitary defect, (hypogonadotropic hypogonadism), while an elevated LH level indicates a primary testicular defect (hypergonadotropic hypogonadism).168 In men with hypogonadotropic hypogonadism, the yield from adjunctive tests (e.g., prolactin measurement, pituitary imaging, iron studies) is increased. Screening questionnaires are not an appropriate tool to identify candidates for testosterone therapy. Thus, pituitary dysfunction can develop after radiation therapy for sellar, parasellar, and extrasellar neoplasms (e.g., craniopharyngiomas, meningiomas, germinomas, chordomas, hemangio-pericytomas, pituicytomas, gliomas), head and neck tumors, and following total body irradiation for systemic malignancies. With worsening Leydig cell function, there is a reduction in the feedback mechanism resulting in elevation of LH levels (hypergonadotropic hypogonadism).
Using very lenient study selection criteria (all types of trials, including observational), Corona et al.325 identified improvements in total cholesterol, triglycerides, and high-density lipoproteins (HDL). A second large RCT by Snyder et al.319 used the Functional Assessment of Chronic Illness Therapy-Fatigue scales (range 0-52) in 474 men treated with testosterone for 12 months. Furthermore, additional testing, such as parathyroid hormone, calcium, and vitamin D levels, may be required. 1-89, 10These results are consistent with other meta-analyses,296 yet methodological flaws in the study design may underestimate the true rate and magnitude of improvement in erectile function. ED is one of the primary reasons that men seek testosterone treatment. Finally, a randomized trial of 76 men (mean age 50.6 years), who had at least 1 ejaculatory dysfunction symptom and at least 2 testosterone tests 182 For men who develop gynecomastia/breast symptoms while on treatment (e.g., breast pain, breast tenderness, nipple tenderness), a period of monitoring based on clinical judgment should be considered, as breast symptoms sometimes abate.
While this period of waiting might preclude the need for testosterone therapy by allowing testosterone to return to normal levels organically, it is possible that men who underwent long courses of ADT may not regain physiological testosterone levels even one year after cessation of ADT.349, 350 It is the opinion of this Panel that until there is definitive evidence demonstrating that testosterone therapy is not safe for use in prostate cancer patients, the decision to commence testosterone therapy in men with a history of prostate cancer is a negotiated decision based on the perceived potential benefit of treatment. The treatment and placebo arms did not differ at baseline in terms of age (62.9 years versus 64.4 years, respectively), total testosterone level (320 ng/dL versus 344 ng/dL, respectively), or PSA measurements (1.3 ng/mL in both arms). Included studies had significant heterogeneity with the populations themselves, methods of assessment, study durations, baseline population characteristics, and number of participants, leading the Panel to conclude that there is currently insufficient evidence to determine if testosterone therapy impacts QoL in a meaningful way. Despite the absence of definitive evidence, the Panel recommends that patients with these symptoms be counseled regarding the possibility of improvement on testosterone therapy.
Scialli Consulting LLC did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Scialli Consulting LLC has no employees and did not support this study with either salary or any other funding. In 2012, sales for testosterone therapies exceeded $2 billion, and sales continue to grow in dozens of countries. However, the direction of causality is unclear; it is possible that obesity or lack of exercise and chronic disease lower testosterone rather than low testosterone concentrations causing disease.
"Normal testosterone ranges are based on morning samples, when the average person is at a higher level. About 40% of men over age 45 will have levels that come in below that range. Testosterone levels are measured through blood tests.
If you’re trying to increase your sex drive, 6 months may do the trick. For example, if you have pituitary disease, you may need therapy for the rest of your life. How long you’ll need therapy can vary, depending on the symptom(s) you’re trying to treat. "Anything that affects overall health affects testosterone," he says.
The testosterone therapeutic space is relatively unique. Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there is no evidence. A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. Where gaps in the evidence existed, the Panel provides guidance in the form of Clinical Principles or Expert Opinion with consensus achieved using a modified Delphi technique if differences of opinion emerged. Conditional Recommendations also can be supported by any evidence strength. Body of evidence strength Grade C is only rarely used in support of a Strong Recommendation. All three statement types may be supported by any body of evidence strength grade.
To minimize these effects, two morning draws for testosterone are recommended before any clinical intervention. To minimize these effects, two morning draws for testosterone are recommended before any clinical intervention.Acute Illness. There are inherent challenges in testosterone measurement due to the health status of patients at the time of testing, circadian rhythms in testosterone production, intra-individual variability, and inconsistencies in the assays themselves. The Panel does not recommend using free testosterone measurements as the primary diagnostic method for testosterone deficiency. Some authorities have advocated that free testosterone should be the primary measure used to define testosterone deficiency. Due to the challenges in testosterone methodology, there is considerable variability in testosterone reference ranges.13 The specific reference ranges used to diagnose testosterone deficiency are discussed in more depth later in this document. - http://awg.bplaced.net/smf/index.php?action=profile;u=87980
